Date post: | 30-May-2018 |
Category: |
Documents |
Upload: | chocoholic-potchi |
View: | 223 times |
Download: | 0 times |
of 43
8/14/2019 HIV Testing CAO.pptx
1/43
Group 4
HIV Testing
8/14/2019 HIV Testing CAO.pptx
2/43
The human immunodeficiency virus (HIV)infection and acquired immunodeficiency syndrome(AIDS) continue to present a major challenge tohealthcare professionals and society through out muchof the world.
Testing for AIDS virus became a cornerstone for
surveillance and prevention programs and for provisionof appropriate medical care for those who are infected.
The controversy surrounding the tests now stemsnot from a lack of confidence in their reliability but fromthe perceived social consequences of an individualbeing identified as infected with the AIDS virus. With
better understanding by the public of HIV infection/AIDSand a greater acceptance of those who are infected,this attitude can be hoped to change.
Introduction
8/14/2019 HIV Testing CAO.pptx
3/43
1981The isolation of human T-lymphotropic virus type 1 (HTLV-I)
ended the skepticism that no retrovirus will be found toinfect humans.
1983 Researchers at the Pasteur Institute in Paris isolated a
retrovirus from a homosexual man with lymphadenopathyand named it lymphadenopathy-related virus (LAV)
1984The human T-lymphotropic retrovirus (HTLV-III) was isolated
by an American research team led by Robert Gallo.
1985The first tests became available to identify antibody to a
retrovirus, the human immunodeficiency virus (HIV). Interval between infection and detection (window period) was
22 days.
8/14/2019 HIV Testing CAO.pptx
4/43
1996Blood banks in the United States added the p24
antigen capture assay to the screening process
to help identify the rare infected individuals whowere donating blood in the time (up to 3 months)between infection and the development ofantibodies.
Window period was 16 days.
2002The licensure of nucleic acid testing (NAT) as a
routine part of blood donor screening allowed the
early detection of HIV infection.Window periods was 12 days.
8/14/2019 HIV Testing CAO.pptx
5/43
StructureHIV has a cylindrical, eccentric nucleoid or core.
The nucleoid contains the HIV genome, which isdiploid. Encoded in the genome are the entirecomplement of genes of the virus. These genes
code for the structural proteins, which are usedto assemble the virus particles, and theregulatory proteins involved in the regulation ofviral gene expression. The surface of HIVmanifests external knoblike structures formed by
the envelope glycoprotein.
Viral Characteristics
8/14/2019 HIV Testing CAO.pptx
6/43
1.The virus attaches to the CD4 membrane receptor and shedsits protein coat, exposing its RNA core.
2.
3.Reverse transcriptase converts viral RNA into proviral DNA.
4.
5.The proviral DNA is integrated into the genome of the hostcell.
6.
7.New virus particles are produced as the result of normalcellular activities of transcription and translation.
8.
9.New particles bud from the cell membrane.
Life Cycle of HIV
8/14/2019 HIV Testing CAO.pptx
7/43
IncidenceAfrica has been the continent hardest hit by HIV
infection and AIDS.
In the USA, 80% of AIDS cases are reported in gayor bisexual men, and 16% are intravenous drugusers, the majority of whom live in majormetropolitan areas.
Epidemiology
8/14/2019 HIV Testing CAO.pptx
8/43
Modes of TransmissionThe modes of transmission of HIV are similar to
those of hepatitis B, in particular with respect tosexual, parenteral, and vertical transmission. Therisk of sexual transmission varies with particularsexual practices.
HIV has been isolated from blood, semen, vaginalsecretions, saliva, tears, breast milk, CSF,amniotic fluid, and urine.
HIV may be indirectlytransmitted.Children born to women with HIV have a 20% to
30% risk of HIV infection.
8/14/2019 HIV Testing CAO.pptx
9/43
Signs and SymptomsMany individuals with HIV infection remain
asymptomatic for years, with a mean time ofapproximately 10 years between exposure anddevelopment of AIDS. When symptoms occur
they may be remarkably protean and nonspecific.Physical examination may be entirely normal.Abnormal findings may range from completelynonspecific to highly specific for HIV infection .
Kaposis sarcoma
8/14/2019 HIV Testing CAO.pptx
10/43
ENZYMEENZYME
IMMUNOASSAYIMMUNOASSAY
HIV ScreeningTest
8/14/2019 HIV Testing CAO.pptx
11/43
Diagnosis of HIV Infection
The CDC has recommended that screening for HIVinfection be performed as a matter of routine healthcare. The diagnosis of HIV infection depends upon
the demonstration of antibodies to HIV and/or thedirect detection of HIV or one of its components. Asnoted above, antibodies to HIV generally appear inthe circulation 2-12 weeks following infection.
8/14/2019 HIV Testing CAO.pptx
12/43
ELISA
The standard blood screening test for HIV infection isELISA, also referred to as an enzyme immunoassay(EIA). The solid-phase assay is an extremely goodscreening test with a sensitivity of >99.5%.
Most diagnostic laboratories use a commercial EIA kit thatcontains antigens from both HIV-1 and HIV-2 and thusare able to detect either.
EIA tests are generally scored as positive (highly reactive)negative (nonreactive), or intermediate (partially active).
8/14/2019 HIV Testing CAO.pptx
13/43
While the EIA is an extremely sensitive test, it is not optimalwith regard to specificity. Among the factors associated withfalse-positive EIA tests are antibodies to class II antigens,autoantibodies, hepatic disease, recent influenzavaccination, and acute viral infection. For these reactions,
anyone suspected of having HIV infection based upon apositive or inconclusive EIA result must have the resultconfirmed with a more specific assay such as the Westernblot.
8/14/2019 HIV Testing CAO.pptx
14/43
Commercial enzyme immunoassay for HIV-1and HIV-2 use several types of anitgens, thatis, whole virus lysate, recombinant proteins,and chemically synthesized peptides. Thefirst FDA-approved assays using a whole
virus lysate antigen remain the mostcommonly used antigen preparation in theUnited States. This is because whole viruslysate antigens contain all the viral proteins
present in the virus.
8/14/2019 HIV Testing CAO.pptx
15/43
EIA Procedures IndirectAssay The EIA screening tests for HIV-1 antibody currentlylicensed in the United States use microwells or
beads coated with antigenic preparations ofinactivated and lysed whole virus.
Diluted patient serum is added to the microwell, andHIV-1 specific antibody, if present, is allowed toreact with the immunosorbent.
Thorough washing is done after incubation to
remove extraneous serum proteins and unboundantibody.
8/14/2019 HIV Testing CAO.pptx
16/43
An enzyme-conjugated second antibody specific forhuman immunoglobulin is added and allowed to react
with antibody bound to the absorbed viral lysate.
An appropriate substrate is added to the microwell, andthe color change resulting from hydrolysis of the
substrate by the enzyme is measuresspectrophotometrically.
This is compared to a reference standard of knownconcentration, this color change is directly proportional
to the amount of HIV-1-specific antibody present in thepatient specimen.
8/14/2019 HIV Testing CAO.pptx
17/43
EIA Procedures CompetitiveAssay
Competitive assay use the same types of antigensas the indirect EIA. These antigens are bound toa solid support, usually a microplate well.
The patients sample (serum or plasma) is added to
the well simultaneously with enzyme-labeled HIVantibody.
During incubation, the patients antibodies competewith the enzyme-labeled HIV antibody for the
limited number of antigen binding sites availableon the walls of the microplate.
8/14/2019 HIV Testing CAO.pptx
18/43
As the concentration of antibody increases in the
patients sample, the enzyme-labeled antibodyis displaced from the antigen binding site andthe color development is less than thatobserved with antibody negative specimens.
In contrast to the indirect assays, the intensity ofthe color change observed in the competitiveEIA is inversely related to the amount of HIV
antibody present in the test sample.
8/14/2019 HIV Testing CAO.pptx
19/43
PARTICLEAGGLUTINATION ASSAYS
HIV Screening Test
8/14/2019 HIV Testing CAO.pptx
20/43
Particle Agglutination Assay
The most widely used test for HIV.The assay is simpler to perform than the
standard EIA and requires practically noequipment.
Well suited for use in large seroprevalencesurveys.
Has been found to be slightly less sensitive
than EIA.
8/14/2019 HIV Testing CAO.pptx
21/43
Procedure
Mix 25 uL of diluted serum with a suspensionof gelatin particles coated with purified HIVantigen.
The assay is performed in a microplate and
can be read after incubating for two hoursat room temperature.
8/14/2019 HIV Testing CAO.pptx
22/43
Results
(+) positive = sera that agglutinate coatedparticles alone.
(-) negative = sera that produce noagglutination.
Sera that agglutinate both coated anduncoated particles are retested.
Positive specimens should be confirmed bythe use of a supplemental assay such asWestern Blot.
8/14/2019 HIV Testing CAO.pptx
23/43
HEMAGGLUTINATIONASSAY
HIV Screening Test
8/14/2019 HIV Testing CAO.pptx
24/43
Hemagglutination Assay
A quantification of viruses or bacteria byhemagglutination.
It is an easy, simple and rapid method andcan be applied to large amounts of
samples.
8/14/2019 HIV Testing CAO.pptx
25/43
LATEX AGGLUTINATIONASSAYS
HIV Screening Test
8/14/2019 HIV Testing CAO.pptx
26/43
Latex Agglutination Assay
Has not gained wide acceptance because ofits cost, difficulty in reading and lack ofsensitivity and specificity compared to EIA.
Very easy to perform and produces results in
less than 10 minutes. Difficult to read even when the appropriate
high-intensity light and magnification areused as recommended.
When performed by well-trained, experiencedtechnologists, the results have been foundto be reliable.
8/14/2019 HIV Testing CAO.pptx
27/43
SOLID-PHASEIMMUNOASSAY
HIV Screening Test
8/14/2019 HIV Testing CAO.pptx
28/43
Solid-Phase ImmunoAssay
Often referred to as rapid tests since resultscan be obtained in 10-15 minutes.
Antigens are reacted with the patients seraand the resulting immune complexes are
trapped on to filters. Detection of immune complexes is by the
sequential reaction with enzyme-anti-human IgG conjugates and then a
precipitating substrate. Color reaction occurs where immune
complexes are present and stains the
8/14/2019 HIV Testing CAO.pptx
29/43
Read as positive or negative based on thepresence of the color reaction as comparedto positive and negative control spots.
Gaining popularity due to their simplicity and
rapid results. Used in situations where standard EIAs
cannot be performed or immediate testresults are required.
8/14/2019 HIV Testing CAO.pptx
30/43
Western blotWestern blot
HIV Screening Test
8/14/2019 HIV Testing CAO.pptx
31/43
More informative followup test for EIA.Standard method for confirming HIV-1
seropositivity.
8/14/2019 HIV Testing CAO.pptx
32/43
ProcedureProcedure
HIV viral protiens are seperated accordingto their molecular weight.
Nitrocellulose is applied to the surface ofthe gel.
To allow the proteins to migrate from thegel to the surface of the nitrocellulosean electric current will be applied.
8/14/2019 HIV Testing CAO.pptx
33/43
Block and washCut the nitrocellulose into strips.Serum will be incubated in the stripIf present, Ab to HIV proteins will bind to
the viral Ag on the surface of thenitrocellulose.
8/14/2019 HIV Testing CAO.pptx
34/43
Proteins:EnvPolGag
Most reports indicate that Ab to gagproteins appear first.
8/14/2019 HIV Testing CAO.pptx
35/43
Disadvantages
Time consuming and expensiveMany source of error
8/14/2019 HIV Testing CAO.pptx
36/43
Immunoflourescence assay
8/14/2019 HIV Testing CAO.pptx
37/43
Commonly used in the labLess expenssive
8/14/2019 HIV Testing CAO.pptx
38/43
Infected cells and uninfected cells aremixed or placed on the separate area ofthe slide. UNINFECTED cells serves asnegative controls.
Incubated with the serum Wash Incubate with flourescencein
isothiocyanate-labeled anti-human IgG.
Observe the flourescence pattern usingflourescent microscope.
8/14/2019 HIV Testing CAO.pptx
39/43
Radioimmunoassay
8/14/2019 HIV Testing CAO.pptx
40/43
2 Techniques
Solid-phaseLiquid-phase
8/14/2019 HIV Testing CAO.pptx
41/43
Solid phaseSolid phase
Microtiter wells are coated withmonoclonal or polyclonal antibody toHIV-1 proteins
Add the sample and incubate
Wash Add the I-labeled IgG (anti-HIV) solution Wash
Cut the wells Radioactivity is measured with gammacounter
8/14/2019 HIV Testing CAO.pptx
42/43
Liquid phaseLiquid phase
Serum or cultured medium containingHIV-1 are mixed with I-labeled IgG in asmall volume liquid
IncubateCentrifugeWashMeasure the radio activity
8/14/2019 HIV Testing CAO.pptx
43/43
AIDS Testing Methodology and Management Issues by Gerald
Schochetman and J. Richard GeorgeBlood, Blood Products and HIV, 2nd Edition by R. Madhok, C.D.
Forbes and B.L. Evatt Immunology and Serology in Laboratory Medicine, 2nd Edition
by Mary Louise Turgeon2006 Current Medical Diagnosis and Treatment, 45th Edition
by Lawrence M. Tierney, Jr. et. al.1991 Medical Diagnosis and Treatment, 30th Edition by
Steven A. Schroeder et. al.Harrisons Principles of Internal Medicine, 17th Edition by
Fauci, Braunwald, Kasper, Hauser, Longo, Jameson,Loscalzo
The Jounal of Infectious Diseases, Volume 162 number 6(December 1990 issue)
References